semaglutide and cardiovascular outcomes in obesity The weight-loss drug Wegovy lowered heart attack risk a large trial Designing Next-Generation Cardiometabolic Outcome Trials

Duffy AM, Holscher C

Average weight loss ranges from 4 to 8 pounds cumulatively for people combining the dose with reasonable food and activity habits

Theres no single perfect number for everyone, but many patients taking GLP-1 medications benefit from aiming for higher protein intake than they were eating previously

Proteccin cardiovascular: Avalado por estudios SUSTAIN, reduce eventos cardacos mayores

Buyer takeaway: the brand's own comparison chart lists identical side-effect language for three of the four options ("typical GLP-1 ramp, titrated gradually") and singles out microdosed tirzepatide as "built to be the gentlest of the four." That's a specific, brand-stated distinction worth weighing if side effects are your primary concern rather than speed of results